Inhibition of metoprolol metabolism by amino acids in perfused rat livers: Insights into the food effect?

Drug Metabolism and Disposition

Volumn 25, Issue 3, 1997, Pages 287-295

  Wang, Bo ^b   Semple, Hugh A ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

METOPROLOL; NADOLOL;

AMINO ACID METABOLISM; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; DRUG MECHANISM; DRUG METABOLISM; ENZYME INHIBITION; FIRST PASS EFFECT; FOOD DRUG INTERACTION; HYPERTENSION; LIVER METABOLISM; LIVER PERFUSION; MALE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RAT; REACTION ANALYSIS; STEADY STATE;

ADRENERGIC BETA-ANTAGONISTS; AMINO ACIDS; ANIMALS; DRUG INTERACTIONS; FOOD; LIVER; MALE; METOPROLOL; OXYGEN; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS;

ANIMALIA;

EID: 0030985586     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. A. Melander, D. Lalka, and A. McLean: Influence of food on the presystemic metabolism of drugs. Pharmacol. Ther. 38, 253-267 (1988).
2. P. Du Souich, H. Maurice, and L. Heroux: Contribution of the small intestine to the first-pass uptake and systemic clearance of propranolol in rabbits. Drug. Metab. Dispos. 23, 279-284 (1995).
3. A. J. McLean, P. J. McNamara, P. duSouich, M. Gibaldi, and D. Lalka: Food, splanchnic blood flow, and bioavailability of drugs subject to first-pass metabolism. Clin. Pharmacol. Ther. 24, 5-10 (1978).
4. C. K. Svensson, D. J. Edwards, P. M. Mauriello, S. H. Barde, A. C. Foster, R. A. Lanc, E. Middleton, and D. Lalka: Effect of food on hepatic blood flow: implications in the "food effect" phenomenon. Clin. Pharmacol. Ther. 34, 316-323 (1983).
5. M. W. Modi, J. M. Hassett, and D. Lalka: Influence of posture on hepatic perfusion and the presystemic biotransformation of propranolol: simulation of the food effect. Clin. Pharmacol. Ther. 44, 268-274 (1988).
6. J. Feely, J. Nadeau, and A. J. J. Wood: Effects of feeding on the systemic clearance of indocyanine green and propranolol blood concentrations and plasma binding. Br. J. Clin. Pharmacol. 15, 383-385 (1983).
7. H. Liedholm and A. Melander: Concomitant food intake can increase the bioavailability of propranolol by transient inhibition of its presystemic primary conjugation. Clin. Pharmacol. Ther. 40, 29-36 (1986).
8. A. J. McLean, C. Isbister, A. Bobik, B. Pharm, and F. J. Dudley: Reduction of first-pass hepatic clearance of propranolol by food. Clin. Pharmacol. Ther. 30, 31-34 (1981).
9. H. Liedholm, B. E. Wahlin, and A. Melander: Mechanisms and variations in the food effect on propranolol bioavailability. Eur. J. Clin. Pharmacol. 38, 469-475 (1990).
10. H. A. Semple, Y. K. Tam, and R. T. Coutts: A computer simulation of the food effect: transient changes in hepatic blood flow and Michaelis-Menten parameters as mediators of hepatic first pass metabolism and bioavailability of propranolol. Biopharm. Drug Dispos. 11, 61-76 (1990).
11. H. A. Semple and F. Xia: Interaction between propranolol and amino acids in the single-pass isolated, perfused rat liver. Drug Metab. Dispos. 24, 794-798 (1995).
12. H. A. Semple and F. Xia: Propranolol disposition in the single-pass isolated, perfused rat liver in the presence and absence of insulin and glucagon. Drug Metab. Dispos. 22, 822-826 (1994).
13. L. L. Miller: Technique of isolated rat liver perfusion. In "Isolated Liver Perfusion and Its Applications" (I. Bartosek, A. Guaitani, and L. L. Miller, eds.), pp. 11-52. Raven Press, New York, 1973.
14. D. H. Elwyn: The role of the liver in regulation of amino acid and protein metabolism. In "Mammalian Protein Metabolism" (H. N. Munro, eds.), pp. 523-557. Academic Press, New York, 1970.
15. V. P. Shah, K. K. Midha, S. Dighe, I. J. McGilveray, J. P. Skelly, A. Yacobi, T. Layloff, C. T. Viswanathan, C. E. Cook, R. D. McDowall, K. A. Pittman, and S. Spector. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J. Pharm. Sci. 81, 309-313 (1992).
16. M. Rowland and T. Tozer: "Clinical Pharmacokinetics." Williams & Wilkins, Baltimore, 1995.
17. K. S. Pang and M. Rowland: Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzyme activity on hepatic drug clearance. J. Pharmacokinet. Biopharm. 5, 625-653 (1977).
18. M. Davies and I. J. Whitting: A modified form of Levenberg's correction. In "Numerical Methods for Non-linear Optimization," chap. 12. Academic Press, New York, 1972.
19. "YSI Model 5300 Biological Oxygen Monitor Instruction Manual." Yellow Springs Instrument Company, Inc., Yellow Springs, OH.
20. K. Balmér, Y. Zhang, Lagerström, and B. E. Persson: Determination of metoprolol and two major metabolites in plasma and urine by column liquid chromatography and fluorometric detection. J. Chromatogr. 417, 357-365 (1987).
21. J. Godbillon and M. Duval: Determination of two metoprolol metabolites in human urine by high performance liquid chromatography. J. Chromatogr. 309, 198-202 (1984).
22. M. S. Lennard: Quantitative analysis of metoprolol and three of its metabolites in urine and liver microsomes by high-performance liquid chromatography. J. Chromatogr. 342, 199-205 (1985).
23. J. H. Anderson, R. C. Anderson, and L. S. Iben: Hepatic uptake of propranolol. J. Pharmacol. Exp. Ther. 206, 172-180 (1978).
24. M. S. Lennard, H. K. Crewe, G. T. Tucker, and H. F. Woods: Metoprolol oxidation by rat liver microsomes: inhibition by debrisoquine and other drugs. Biochem. Pharmacol. 35, 2757-2761 (1986).
25. A. Arfwidsson, K. O. Borg, K.-J. Hoffmann, and I. Skanberg: Metabolism of metoprolol in the rat in vitro and in vivo. Xenobiotica 6, 691-711 (1976).
26. 3H) in the rat and the dog. Acta Pharmacol. Toxicol. 36, 104-115 (1975).
27. J. B. Houston: Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47, 1469-1479 (1994).
28. S. V. Otton, H. K. Crewe, M. S. Lennard, G. T. Tucker, and H. F. Woods: Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. J. Pharmacol. Exp. Ther. 247, 2427 (1988).
29. Y. K. Tam: Individual variation in first-pass metabolism. Clin. Pharmacokinet. 25, 300-328 (1993).
30. M. Kim, D. D. Shen, A. C. Eddy, W. L. Nelson, and L. K. Roskos: Inhibition of the enantioselective oxidative metabolism of metoprolol by verapamil in human liver microsomes. Drug Metab. Dispos. 21, 309-317 (1993).
31. S. Fujita, S. Umeda, Y. Funae, S. Imaoka, H. Abe, R. Ishida, T. Adachi, M. Masuda, A. Kazusaka, and T. Suzuki: Regio- and stereoselective propranolol metabolism by 15 forms purified cytochromes P-450 from rat liver. J. Pharmacol. Exp. Ther. 264, 226-233 (1993).
32. R. G. Thurman, F. C. Kauffman, and J. Baron: Biotransformation and zonal toxicity. In "Regulation of Hepatic Metabolism" (R. G. Thurman, F. C. Kauffman, and K. Jungermann, eds.), pp. 321-382. Plenum, New York, 1986.
33. R. G. Thurman, S. Ji, and J. J. Lemasters: Lobular oxygen gradients: possible role in alcohol-induced hepatotoxicity. In "Regulation of Hepatic Metabolism" (R. G. Thurman, F. C. Kauffman, and K. Jungermann, eds.), pp. 293-320. Plenum, New York, 1986.
34. S. Seifter and S. Englard: Energy metabolism. In "The Liver: Biology and Pathobiology" (I. M. Arias, ed.), pp. 323-364. Raven Press Ltd., New York, 1994.
35. K. S. Pang and J. A. Terrell: Retrograde perfusion to probe the heterogeneous distribution of hepatic drug metabolizing enzymes in rats. J. Pharmacol. Exp. Ther. 216, 339-346 (1981).
36. S. L. Elliott, D. J. Morgan, P. W. Angus, H. Ghabrial, R. G. Watson, and R. A. Smallwood: The effect of hypoxia on propranolol clearance during antegrade and retrograde flow in the isolated perfused rat liver preparation. Biochem. Pharmacol. 45, 573-578 (1993).
37. K. S. Pang: Liver perfusion studies in drug metabolism and drug toxicity. In "Drug Metabolism and Drug Toxicity" (J. R. Mitchell and M. G. Horning, eds.), pp. 331-352. Raven Press, New York, 1984.
38. D. B. Jones, G. W. Mihaly, R. A. Smallwood, L. K. Webster, D. J. Morgan, and N. P. Madsen: Differential effects of hypoxia on the disposition of propranolol and sodium taurocholate by the isolated perfused rat liver. Hepatology 4, 461-466 (1984).
39. S. L. Elliott, D. J. Morgan, P. W. Angus, H. Ghabrial, and R. A. Smallwood: Sensitivity of propranolol elimination to hypoxia in the isolated perfused rat liver preparation. Clin. Exp. Pharmacol. Physiol. 20, 27-33 (1993).
40. T. Brundin and J. Wahren: Influence of protein ingestion on human splanchnic and whole-body oxygen consumption, blood flow, and blood temperature. Metabolism 43, 626-632 (1994).
41. M. Dauzat, M. Lafortune, H. Patriquin, and G. Pomier Layrargues: Meal induced changes in hepatic and splanchnic circulation: a noninvasive Doppler study in normal humans. Eur. J. Appl. Physiol. 68, 373-380 (1994).
42. J. M. Power, D. J. Morgan, and A. J. McLean: Effects of sensory (teasing) exposure to food on oral propranolol bioavailability. Biopharm. Drug Dispos. 16, 579-589 (1995).